The Leading Global Pharmaceutical Company, Lupin has made an announcement on Thursday that they are going to enter into the digital healthcare business soon. Through this step, they want to make an entry for providing an excellent digital therapeutics platform to doctors and patients across India. Along with this, the company said in an exchange filing,” The Board Directors of the company has given their approval to the company’s entry into the digital healthcare platform to provide excellent and emerging facility to the doctors and patients across the nation”.
Recently, the company includes a new authority in the name of Lupin Digital Health Limited, which is owned subsidiary of the Lupin company and it will handle all the responsibility of the company. After the announcement made, the share of Lupin was trading at Rs 1,245 per share on BSE which is lower than 0.15%.
According to the shareholding pattern of March 2021 Lupin, Rakesh Jhunjhunwala has a holding share of 72,45,605 and which is a 1.6% of partnering share in the company. In the quarter of December 2020, Rakesh Jhunjhunwala had a partnership of the same shares holding in the company.
In the month of May, the Chief Executive Officer of Lupin Limited, Vinita Gupta said that the company is trying to collecting the documents related to the license of Covid-19 medicines and drugs because the producing company was missed out on launching the medicines during the first wave of Covid-19. Later Gupta added that they are also trying to search for Pfizer and Modern for the vaccines of Covid-19. Vinita Gupta said,” the company is not close yet regarding any agreements of this.
Along with the above-given information, the company recently a partnership with Eli Lily and Company for Baricitinob, which is a drug that can be used for producing and treatment of Covid-19 vaccines. With this information, the company also revealed that it will take at least a couple of months to launch this in the Indian market.
The Lupin Global Pharmaceutical Company is a leading multinational company that is currently working on the vaccines related to the Covid-19 pandemic and maybe, they are planning to get ready for the third wave of the Covid-19 in India because they missed out on many things in the second wave. This thing is also affecting the share prize of the company and maybe, the company will release soon more information regarding to the their new announcement. Stay tuned with us, we will provide you more updates regarding the business news.
